Department of Pulmonary & Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, China.
The Center for Clinical Molecular Medical Detection of Chongqing, The First Affiliated Hospital of Chongqing Medical University, No. 1 Youyi Road, Yuanjiagang, Yuzhong District, Chongqing, 400016, China.
Future Oncol. 2021 Jul;17(19):2475-2488. doi: 10.2217/fon-2021-0064. Epub 2021 Mar 26.
This study investigated the association between clinical data and T790M mutation in rebiopsy after EGFR tyrosine kinase inhibitors (EGFR-TKIs) failure, and explored the prognosis of T790M-positive patients. Patients with non-small-cell lung cancer undergoing rebiopsy after first-generation TKI failure were reviewed. Patients with brain metastases, negative TP53, initial 19del and longer initial PFS had higher positive rate of T790M. The median progression-free survival (PFS) of T790M-positive patients with cytology and tissue rebiopsy were longer than patients with liquid rebiopsy. The median PFS of T790M-positive patients rebiopsied by ordinary bronchoscope and endobronchial ultrasound-guided transbronchial lung biopsy with a guided sheath (EBUS-GS-TBLB) were longer than that of the patients rebiopsied by EBUS transbronchial needle aspiration (TBNA).
本研究探讨了 EGFR 酪氨酸激酶抑制剂（EGFR-TKIs）失败后再次活检的临床数据与 T790M 突变之间的关系，并探讨了 T790M 阳性患者的预后。回顾了第一代 TKI 治疗失败后行再次活检的非小细胞肺癌患者。脑转移、TP53 阴性、初始 19del 和初始 PFS 较长的患者 T790M 阳性率更高。细胞学和组织再次活检的 T790M 阳性患者的中位无进展生存期（PFS）长于液体再次活检的患者。普通支气管镜和支气管内超声引导经支气管肺活检带鞘（EBUS-GS-TBLB）引导下的 T790M 阳性患者的中位 PFS 长于经支气管内超声引导针吸活检（TBNA）的患者。
